GMDA - Gamida Cell Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Gamida Cell Ltd.

5 Nahum Heftsadie Street
Givaat Shaul
Jerusalem 91340
972 2 659 5666

Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Dr. Julian AdamsCEO & Director580kN/A1955
Mr. Shai LankryChief Financial Officer200kN/A1976
Dr. Ronit SimantovChief Medical Officer436kN/A1965
Mr. Joshua D. Hamermesh MBAChief Bus. Officer283kN/A1972
Dr. Tony PeledCo-Founder, CTO and VP of R&DN/AN/A1954
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Corporate Governance

Gamida Cell Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.